Specifically, on February 6, 2017, the Israeli publication Calcalist reported that Kitov's chief executive officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority. Citing court documents, the publication also stated that the Company might have published misleading information regarding findings from an independent committee appointed to check clinical trial results of one of the Company's drugs.
Request more information now by clicking here: www.faruqilaw.com/KTOV. There is no cost or obligation to you.
If you invested in Kitov stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/KTOV. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Kitov's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ktov-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-kitov-pharmaceutical-holdings-ltd-to-contact-the-firm-300403416.html
SOURCE Faruqi & Faruqi, LLP